Blueprint’s latest approval for Ayvakit sets up clash with NovartisBlueprint Medicines has claimed its second FDA approval for Ayvakit, getting the nod for advanced systemic mastocytosis (SM), Share XBlueprint’s latest approval for Ayvakit sets up clash with Novartishttps://pharmaphorum.com/news/blueprints-latest-approval-for-ayvakit-sets-up-clash-with-novartis/
